Abstracts Archive - Page 866 of 2607 - ACR Meeting Abstracts

Abstract Number: 0444 • ACR Convergence 2020
Chronological Order of Decrease of Synovitis, Osteitis and Tenosynovitis in Early Arthritis Patients Receiving First DMARD-treatment
Xanthe Matthijssen¹, Ellis Niemantsverdriet¹, Saskia le Cessie¹ and Annette van der Helm - van Mil², ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Advanced imaging modalities have shown that not only joints but also bones and tendon sheaths can be inflamed at diagnosis of rheumatoid arthritis. We…
Abstract Number: 0445 • ACR Convergence 2020
Dual-Energy CT in Gout Patients: Do All Color-Coded Lesions Actually Represent Monosodium Urate Crystals?
Sara Christiansen¹, Felix Müller², Mikkel Østergaard³, Ole Slot¹, Jakob Møller², Henrik Børgesen², Kasper Gosvig² and Lene Terslev⁴, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Glostrup, Denmark, ²Department of Radiology, Herlev and Gentofte Hospital, Herlev, Denmark, ³Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Copenhagen, Denmark
Background/Purpose: Dual-Energy CT (DECT) can acknowledge differences in tissue compositions and can color-code tissues with specific features including monosodium urate (MSU) crystals. However, when evaluating…
Abstract Number: 0446 • ACR Convergence 2020
Novel Ultrasound Image Acquisition Protocol and Scoring System for the Pediatric Ankle
Patricia Vega-Fernandez¹, Deirdre De Ranieri², Edward Oberle³, Hulya Bukulmez⁴, Clara Lin⁵, Susan Shenoi⁶, Akaluck Thatayatikom⁷, Leandra Woolnough⁸, Kathleen Jo Corbin⁹, Heather Benham¹⁰, Emily Brunner¹¹, Michael Henrickson¹, Laura Ballenger³, Sara Haro¹², Christina Schutt¹³, Jean-Philippe Proulx-Gauthier¹⁴, Ginger Janow¹⁵, Mekibib Altaye¹⁶, Amy Cassedy¹, Johannes Roth¹⁷ and Tracy Ting¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Lurie Children's Hospital, Chicago, IL, ³Nationwide Children's Hospital, Columbus, OH, ⁴MetroHealth Medical Center, Case Western Reserve, Pepper Pike, OH, ⁵Children's Hospital Colorado, Aurora, CO, ⁶Seattle Childrens Hospital, seattle, WA, ⁷Department of Pediatrics, University of Florida, Gainesville, FL, ⁸University of Florida, Gainesville, FL, ⁹Yale University School of Medicine, Woodbridge, CT, ¹⁰Texas Scottish RIte Hospital, North Richland Hills, TX, ¹¹Geisinger, Bloomsburg, PA, ¹²UCSF, San Francisco, CA, ¹³University of Pittsburgh Medical Center, Pittsburgh, PA, ¹⁴CHU de Quebec - Universite Laval, Quebec, Canada, ¹⁵Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, NJ, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, ¹⁷University of Ottawa, Ottawa, ON, Canada
Background/Purpose: The clinical decision-making process in pediatric arthritis lacks an objective, reliable bedside imaging tool. Although increasingly used for children, there is a need for…
Abstract Number: 0447 • ACR Convergence 2020
Magnetic Resonance Imaging Characteristics in Patients with Spondyloarthritis and Clinical Diagnosis of Heel Enthesitis: Screening Data from a Phase 3 Trial
Xenofon Baraliakos¹, Philipp Sewerin², Eugenio De Miguel³, Christine Kleinmond⁴, Ankita Shekhawat⁵, Claudia Jentzsch⁶, Annette Wiedon⁷ and Frank Behrens⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴ClinProject GmbH, Eurasburg, Germany, ⁵Novartis Healthcare Private Limited, Hyderabad, Telangana, India, ⁶Novartis Pharma GmbH, Nuremberg, Germany, ⁷Novartis Pharma GmbH, Nurnberg, Germany, ⁸CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany
Background/Purpose: Inflammation and pain at entheseal sites are the key clinical signs in patients (pts) with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).1 Magnetic resonance…
Abstract Number: 0448 • ACR Convergence 2020
Disease-related factors associated to atherosclerotic disease in axial spondyloarthritis. A mutlicenter study with 806 patients.
Inigo Gonzalez-Mazon¹, Ivan Ferraz-Amaro², Javier Rueda-Gotor³, Lara Sanchez-Bilbao⁴, David Martinez-Lopez⁵, Mario Agudo-Bilbao³, Fernanda Genre⁶, Sara Remuzgo-Martínez⁶, Veronica Pulito-Cueto⁶, Alfonso Corrales⁷, Leticia Lera-Gómez⁶, Virginia Portilla⁶, Vanesa Calvo-Río³, Cristina Mata⁸, Vanesa Hernández-Hernández⁹, Santos Castañeda¹⁰, Esther Francisca Vicente-Rabaneda¹¹, C Fernandez-Carballido¹², M Paz Martínez-Vidal¹³, David Castro-Corredor¹⁴, Joaquín Anino-Fernández¹⁴, Juan Carlos Quevedo-Abeledo¹⁵, Carlos Rodríguez-Lozano¹⁶, C. Fernandez-Diaz¹⁷, Esther Montes-Perez¹⁸, María Luz García Vivar,¹⁹, Eva Galínez-Agirregoikoa¹⁹, Javier Llorca²⁰, Raquel López-Mejías⁶, Chamaida Plasencia²¹, Diana Peiteado²², Alejandro Balsa-Criado²³, Nuria Barbarroja²⁴, Lourdes Ladehesa-Pineda²⁵, Rafaela Ortega-Castro²⁶, Eduardo Collantes-Estévez²⁵, Ricardo Blanco⁴ and Miguel Ángel González-Gay²⁷, ¹Hospital Universitario Marques de Valdecilla, Bezana, Spain, ²Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³H.U. Marques de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁶Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁷Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁸Hospital de Laredo, Santander, Spain, ⁹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁰Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ¹¹Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ¹²H San Juan, Alicante, Spain, ¹³Hospital General Universitario de Alicante, Alicante, Spain, ¹⁴Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹⁵Hospital Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁷H. Marqués de Valdecilla, Madrid, Spain, ¹⁸Diagnóstico Médico Cantabria (DMC), Santander, Spain, ¹⁹Hospital Universitario Basurto, Bilbao, Spain, ²⁰School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ²¹Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, ²²Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ²³HOSPITAL UNIVERSITARIO LA PAZ, madrid, Spain, ²⁴Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²⁵Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ²⁶Hospital Universitario Reina Sofía, Córdoba, Spain, ²⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Cardiovascular (CV) mortality and morbidity is increased in ankylosing spondylitits (AS) due to a process of accelerated atherosclerosis. The disease-related factors involved in this…
Abstract Number: 0449 • ACR Convergence 2020
Cytotoxic T Cells with a Chronic Antigen Exposure Phenotype Drive Immune Checkpoint Inhibitor Sicca
Blake Warner¹, Billel Gasmi², David Kleiner³, Paola Perez Riveros⁴, Daniel Barber⁵, Shunsuke Sakai⁵ and Alan Baer⁶, ¹National Institute of Dental and Craniofacial Research, Bethesda, ²National Cancer Institute, Bethesda, MD, ³National Cancer Institute, Bethesda, ⁴National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁵National Institute of Allergy and Infectious Disease, Bethesda, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICI) have advanced the field of cancer therapeutics. By blocking the negative co-stimulation of T cells, ICI augment the anti-tumor immune…
Abstract Number: 0450 • ACR Convergence 2020
In Vitro Characterization of Inflammatory Arthritis Associated with Immune Check Point Inhibition
Anne Sofie Sørensen¹, Morten Nørgaard Andersen¹, Kristian Juul-Madsen², Cæcilie Deisting Skejø¹, Henrik Schmidt¹, Thomas Vorup-Jensen¹ and Tue Wenzel Kragstrup¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University, Aarhus, Midtjylland, Denmark
Background/Purpose: During treatment with immune checkpoint inhibitors (ICI) such as the anti-PD-1 antibody pembrolizumab, 2-4% of cancer patients develop inflammatory arthritis as an immune-related adverse…
Abstract Number: 0451 • ACR Convergence 2020
Prevalence, Therapy and Tumor Response in Patients with Rheumatic Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy: A Single-Centre Analysis
Sophia Verspohl¹, Tobias Holderried¹, Charlotte Behning², Peter Brossart¹ and Valentin Schaefer³, ¹Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Institute for Medical Biometrics, Informatics and Epidemiology (IMBIE), University Hospital Bonn, Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ³Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Immune checkpoint inhibitors (ICIs) have improved cancer therapy [1] by inducing a higher immune system activity and subsequent attack of tumor cells. However, this effect…
Abstract Number: 0452 • ACR Convergence 2020
Recombinant Zoster Vaccine in Patients with Rheumatic Diseases: A Retrospective Study of 622 Patients
Tiphaine Lenfant¹, Elizabeth Kirchner², Rula Hajj-ali³, Leonard Calabrese³ and Cassandra Calabrese³, ¹Cleveland Clinic Foundation, Rocky River, OH, ²Cleveland Clinic Foundation, Cleveland, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: The recombinant herpes zoster vaccine (RZV) was FDA-approved in 2017 but patients with rheumatic diseases were excluded from initial pivotal trials because of theoretical…
Abstract Number: 0453 • ACR Convergence 2020
Monitoring of BK Reactivation and Long-term Safety on JAK1/2 Inhibition with Baricitinib
Kader Cetin Gedik¹, Gema Souto Adeva², Jenna Wade¹, Gina Montealegre Sanchez³, Adriana de Jesus⁴ and Raphaela Goldbach-Mansky⁵, ¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ²Translational Autoinflammatory Disease Section (TADS)/NIAID/ NIH, Bethesda, ³Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Rockville, MD, ⁴Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, ⁵Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD
Background/Purpose: Baricitinib has been used to treat pediatric patients (pts) with Type 1 Interferonopathies1. Safety profile including BK viral reactivation in urothelium and pharmacokinetic model…
Abstract Number: 0454 • ACR Convergence 2020
Anticytokine Therapies for Inflammatory Rheumatic Disease (IRD) Are Associated with Reduced Hospitalisation Following Community COVID-19 Infection; Results of the Trinity Rheumatology and Covid-19 Registry – TRACR
Rachael Flood¹, Richard Conway², David Kane¹ and Ronan Mullan¹, ¹Tallaght University Hospital, Dublin, Ireland, ²St James's Hospital, Dublin, Ireland
Background/Purpose: Anticytokine biological disease modifying anti-rheumatic drugs (bDMARD), which are widely prescribed for Inflammatory Rheumatological Diseases (IRD) are currently undergoing clinical trials for the treatment…
Abstract Number: 0455 • ACR Convergence 2020
HLA-B27 and Host Immune Response: Lessons from Reactive Arthritis
Sophie Wojcik¹, Davina Morris², Gillian Fitzgerald³, Steve Ramkissoon⁴, Nigil Haroon² and Robert Inman⁵, ¹UHN, Montreal, QC, Canada, ²University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, ⁴UHN, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada
Background/Purpose: The natural history of reactive arthritis (ReA) remains poorly understood. Certain patients with ReA will go on to develop a chronic course while others…
Abstract Number: 0456 • ACR Convergence 2020
Reduced Risk of Serious Pneumococcal Infection up to 10 Years After Immunization with 7-valent Conjugated Pneumococcal Vaccine in Patients with Inflammatory Arthritis
Johanna Nagel¹, Göran Jönsson², Jan Åke Nilsson³, Chanchai Manuswin⁴, Martin Englund⁵, Tore Saxne¹, Pierre Geborek¹ and Meliha Kapetanovic¹, ¹Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, ²Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, ⁴Centre of Registers South, Skåne University Hospital, Lund, Sweden, Lund, Sweden, ⁵Lund University, Lund, Sweden
Background/Purpose: The aim was to examine the rates of putative pneumococcal infections up to 10 years before and after administration of heptavalent conjugated pneumococcal vaccine…
Abstract Number: 0457 • ACR Convergence 2020
Improving Pneumococcal Vaccination Rates in Immunosuppressed Rheumatology Patients
Julia Harris¹, Michael Holland², Emily Fox², Amy Ivy³, Maria Ibarra², Cara Hoffart², Jordan Jones², Leslie Favier⁴ and Ashley Cooper², ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Kansas City, Kansas City, MO, ³Children's Mercy Kansas City, Kansas City, ⁴Children's Mercy Kansas City, Leawood, KS
Background/Purpose: The Centers for Disease Control and Prevention recommends pneumococcal vaccination of high-risk patients, including patients on iatrogenic immunosuppression. Many patients seen in the rheumatology…
Abstract Number: 0458 • ACR Convergence 2020
Rapid Implementation of a Multidisciplinary COVID-19 Cytokine Storm Syndrome Task Force
Bibi Ayesha¹, Anand Kumthekar¹, Ruchi Jain², Sneha Patel³, Manish Ramesh¹, Denisa Ferastraoaru⁴, Golda Hudes⁴, Merhunisa Karagic⁴, Sheema Zafar¹, Rachel Bartash⁴, Natalia Vasquez-Canizares⁵, Elizabeth Kitsis⁶, Clement Tagoe⁷, Dawn Wahezi⁵, Tamar Rubinstein⁸ and Anna Broder³, ¹Montefiore Medical Center, Bronx, NY, ²Montefiore Medical Center, Irvington, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁴Montefiore Medical Center, Bronx, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Albert Einstein College of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Fresh Meadows, NY, ⁸Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY
Background/Purpose: Coronavirus disease (COVID-19) infected patients present with a state of ongoing inflammation and an exaggerated inflammatory state due to unregulated cytokine release called the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].